Boston, MA -- (SBWIRE) -- 02/18/2014 -- We forecast weak pharmaceutical market growth over the next decade, in light of Croatia's acceding to EU pressure to rein in its budget deficit in December 2013. The budget for 2014 contains major cuts to healthcare funding, with pharmaceuticals expected to bear the brunt. Liquidity issues and payment terms will remain unfavourable in 2014, but we believe that EU pressure should see them ease over the medium term. Healthcare spending is projected to rise over the next 10 years in line with a rapidly ageing population.
Headline Expenditure Projections
- Pharmaceuticals: HRK6.95bn (US$1.19bn) in 2013 to HRK6.74bn (US$1.10bn) in 2014; -3.0% in local currency and -7.4% in US dollar terms.
- Healthcare: HRK26.44bn (US$4.53bn) in 2013 to HRK27.14bn (US$4.44bn) in 2014; 2.7% in local currency and -1.9% in US dollar terms.
View Full Report Details and Table of Contents
Croatia's Risk/Reward Rating is unchanged from Q114. Despite the country's accession to the EU, market dynamics remain subdued, with weak growth over the long term. Croatia scores 45.5 out of 100 in our Risk/ Reward Ratings, making it the 18th most-attractive pharmaceutical market in Central and Eastern Europe.
Key Trends And Developments
- In December 2013, the Croatian parliament approved a draft budget for 2014 that reduced healthcare spending, in order to rein in the country's large budget deficit.
- In July 2013 Croatian healthcare workers lost their collective bargaining rights, paving the way for potential cuts to the number of doctors and health workers, or across-the-board wage cuts for medical staff employed by public hospitals.
- In June 2013 the Croatian government decided to terminate all agreements for services from private hospitals. Previously, the HZZO paid almost HRK500mn (US$87mn) to private providers for services provided, but these will now migrate over to public polyclinics, which are expected to come under stress from an influx of new
BMI Economic View: We hold a below-consensus forecast on Croatian economic growth in 2014, with a sluggish recovery to be undermined by ongoing deleveraging in the consumer and government sectors. We forecast real GDP to expand by just 0.4% in 2014, and caution the risks to our outlook remain weighted firmly to the downside, with the country having made only limited progress rebalancing its economy since the financial crisis.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Australia Pharmaceuticals & Healthcare Report Q2 2014
- Nigeria Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Algeria Pharmaceuticals & Healthcare Report Q2 2014
- South Korea Pharmaceuticals & Healthcare Report Q2 2014
- Malaysia Pharmaceuticals & Healthcare Report Q1 2014
- Furiex Pharmaceuticals, Inc. (FURX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Bayer Healthcare Pharmaceuticals - SWOT, Strategy and Corporate Finance Report
- Bayer HealthCare Pharmaceuticals Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile